Invention Grant
- Patent Title: Fused bicyclic inhibitors of menin-MLL interaction
-
Application No.: US16789707Application Date: 2020-02-13
-
Publication No.: US10975100B2Publication Date: 2021-04-13
- Inventor: Patrick Rene Angibaud , Vineet Pande , Barbara Herkert , Daniel Jason Krosky , Olivier Alexis Georges Querolle , Aaron Nathaniel Patrick
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Agency: BakerHostetler
- Priority: EP16192424 20161005,EP17180228 20170707
- Main IPC: C07D519/00
- IPC: C07D519/00 ; A61P35/02 ; A61P3/10
Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
Public/Granted literature
- US20200172556A1 FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION Public/Granted day:2020-06-04
Information query
